Invenomic Capital Management LP Raises Stock Holdings in Teladoc Health, Inc. $TDOC

Key Points

• Invenomic Capital Management LP has increased its stake in Teladoc Health, Inc. by 36.3%, owning a total of 1,327,128 shares valued at approximately $10.56 million as of the end of the most recent quarter.
• Teladoc Health's earnings report showed a loss of $0.19 per share for the quarter, which was better than the expected loss of $0.27, and revenue of $631.90 million, exceeding estimates.
• The company has a market capitalization of $1.35 billion and a consensus rating of "Hold" from analysts, with a target price averaging around $9.80.

Invenomic Capital Management LP lifted its stake in Teladoc Health, Inc. (NYSE:TDOC - Free Report) by 36.3% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,327,128 shares of the health services provider's stock after purchasing an additional 353,478 shares during the period. Invenomic Capital Management LP owned about 0.76% of Teladoc Health worth $10,564,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Point72 Asset Management L.P. increased its holdings in Teladoc Health by 33.6% in the 4th quarter. Point72 Asset Management L.P. now owns 11,179,863 shares of the health services provider's stock valued at $101,625,000 after purchasing an additional 2,813,568 shares in the last quarter. Two Sigma Investments LP bought a new stake in shares of Teladoc Health during the fourth quarter worth $18,348,000. Two Sigma Advisers LP raised its stake in Teladoc Health by 213.0% in the 4th quarter. Two Sigma Advisers LP now owns 2,258,711 shares of the health services provider's stock worth $20,532,000 after purchasing an additional 1,537,094 shares in the last quarter. Nuveen LLC bought a new stake in Teladoc Health during the 1st quarter worth approximately $11,789,000. Finally, Vanguard Group Inc. raised its holdings in Teladoc Health by 7.0% during the first quarter. Vanguard Group Inc. now owns 19,752,338 shares of the health services provider's stock worth $157,229,000 after buying an additional 1,289,183 shares during the last quarter. Institutional investors and hedge funds own 76.82% of the company's stock.

Teladoc Health Trading Down 1.5%

NYSE TDOC opened at $7.65 on Friday. The company has a 50 day moving average price of $7.79 and a 200 day moving average price of $7.89. Teladoc Health, Inc. has a 52 week low of $6.35 and a 52 week high of $15.21. The firm has a market cap of $1.35 billion, a PE ratio of -6.42 and a beta of 1.84. The company has a quick ratio of 2.58, a current ratio of 2.67 and a debt-to-equity ratio of 0.70.

Teladoc Health (NYSE:TDOC - Get Free Report) last issued its quarterly earnings results on Tuesday, July 29th. The health services provider reported ($0.19) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.27) by $0.08. The company had revenue of $631.90 million during the quarter, compared to the consensus estimate of $621.91 million. Teladoc Health had a negative net margin of 8.16% and a negative return on equity of 10.13%. The firm's quarterly revenue was down 1.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.38) earnings per share. Teladoc Health has set its Q3 2025 guidance at -0.350--0.200 EPS. FY 2025 guidance at -1.350--1.000 EPS. As a group, sell-side analysts forecast that Teladoc Health, Inc. will post -1.16 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently commented on TDOC. Mizuho started coverage on shares of Teladoc Health in a research report on Friday, July 25th. They set a "neutral" rating and a $10.00 price objective on the stock. Evercore ISI raised their target price on Teladoc Health from $7.00 to $8.00 and gave the company an "in-line" rating in a report on Wednesday, July 9th. Wells Fargo & Company reduced their price objective on Teladoc Health from $10.00 to $8.00 and set an "equal weight" rating on the stock in a research report on Thursday, May 8th. Bank of America reduced their price objective on Teladoc Health from $8.00 to $7.00 and set a "neutral" rating for the company in a research report on Wednesday, May 28th. Finally, Truist Financial cut their price objective on Teladoc Health from $10.00 to $9.00 and set a "hold" rating for the company in a research report on Tuesday, May 27th. Six equities research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. Based on data from MarketBeat, Teladoc Health has a consensus rating of "Hold" and a consensus target price of $9.80.

Teladoc Health Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.

Want to see what other hedge funds are holding TDOC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teladoc Health, Inc. (NYSE:TDOC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.